
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>Clinical Trials</title>
  <link rel="stylesheet" href="styles.css" />
</head>
<body>
  <header><h1>Clinical Trials</h1></header>
  <nav><a href="index.html">Back to Home</a></nav>

<main>
    <section>
      <h2>What are Clinical Trials?</h2>
      <p>Clinical trials are research studies conducted in humans to evaluate the safety, efficacy, and optimal use of new drugs, biologics, or medical devices. They are a critical step in the drug development process and are required for regulatory approval.</p>
    </section>

    <section>
      <h2>Phases of Clinical Trials</h2>
      <ul>
        <li><strong>Phase I:</strong> First-in-human studies with a small number of healthy volunteers or patients to assess safety, dosage, and pharmacokinetics.</li>
        <li><strong>Phase II:</strong> Studies in a larger group of patients to evaluate efficacy, optimal dosing, and side effects.</li>
        <li><strong>Phase III:</strong> Large-scale trials to confirm efficacy, monitor adverse reactions, and compare with standard treatments.</li>
        <li><strong>Phase IV:</strong> Post-marketing studies to gather additional information on risks, benefits, and long-term effects.</li>
      </ul>
    </section>

    <section>
      <h2>Study Design</h2>
      <ul>
        <li>Randomized controlled trials (RCTs)</li>
        <li>Double-blind and placebo-controlled designs</li>
        <li>Parallel and crossover designs</li>
        <li>Adaptive trial designs</li>
        <li>Endpoints: primary, secondary, surrogate</li>
      </ul>
    </section>

    <section>
      <h2>Regulatory Requirements</h2>
      <ul>
        <li>Investigational New Drug (IND) application</li>
        <li>Institutional Review Board (IRB) approval</li>
        <li>Informed consent from participants</li>
        <li>Good Clinical Practice (GCP) compliance</li>
        <li>Clinical trial registration (e.g., ClinicalTrials.gov)</li>
      </ul>
    </section>

    <section>
      <h2>Technologies and Tools</h2>
      <ul>
        <li>Electronic data capture (EDC) systems</li>
        <li>Remote monitoring and telemedicine</li>
        <li>Wearable devices and digital biomarkers</li>
        <li>Real-world evidence and electronic health records (EHR)</li>
        <li>AI for patient recruitment and data analysis</li>
      </ul>
    </section>

    <section>
      <h2>Challenges in Clinical Trials</h2>
      <ul>
        <li>Patient recruitment and retention</li>
        <li>High costs and long durations</li>
        <li>Regulatory complexity and global harmonization</li>
        <li>Data integrity and protocol deviations</li>
        <li>Ethical considerations and informed consent</li>
      </ul>
    </section>

    <section>
      <h2>Real-World Examples</h2>
      <ul>
        <li><strong>COVID-19 vaccines:</strong> Rapid global trials for mRNA and viral vector vaccines.</li>
        <li><strong>Oncology trials:</strong> Precision medicine approaches using biomarkers.</li>
        <li><strong>Rare diseases:</strong> Adaptive designs and patient-centric endpoints.</li>
      </ul>
    </section>

    <section>
      <h2>Future Directions</h2>
      <ul>
        <li>Decentralized and virtual trials</li>
        <li>Integration of genomics and personalized medicine</li>
        <li>Blockchain for data transparency and security</li>
        <li>Global trial networks and harmonized regulations</li>
        <li>Patient engagement and advocacy in trial design</li>
      </ul>
    </section>
  </main>

  <footer><p>&copy; 2025 Drug Discovery Knowledge Base</p></footer>
</body>
</html>
